Observational studyActa orthopaedica2015
Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
Observational study in Acta orthopaedica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Efficacy of medical treatment for Charcot neuroarthropathy: a systematic review and meta-analysis of randomized controlled trials.Acta diabetologica · 2021Pooled it
- Trial
- Diabetic Charcot Neuroarthropathy: A Contemporary Review of Molecular and Genetic Markers.Foot & ankle international · 2026Review
- Charcot foot disease: A new approach.Drugs & aging · 2025Review
- Recent Advances in Biomolecular Patho-Mechanistic Pathways behind the Development and Progression of Diabetic Neuropathy.Biomedicines · 2024Review
- The inhibition of Wnt signaling attenuates RANKL-induced osteoclastogenic macrophage activation.Vascular biology (Bristol, England) · 2023Article
- Fractures and dislocations of the foot and ankle in people with diabetes: a literature review.Therapeutic advances in endocrinology and metabolism · 2023Review
- Cartilage Damage Pathological Characteristics of Diabetic Neuropathic Osteoarthropathy.Analytical cellular pathology (Amsterdam) · 2023Article
- Novel Biomarkers Predictive of Diabetic Charcot Foot-An Overview of the Literature.Life (Basel, Switzerland) · 2022Review
- Dysregulation of Wnt signaling in bone of type 2 diabetes mellitus and diabetic Charcot arthropathy.BMC musculoskeletal disorders · 2022Article
- Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study.Medicina (Kaunas, Lithuania) · 2022Article
- Molecular mechanisms of developmental pathways in neurological disorders: a pharmacological and therapeutic review.Open biology · 2022Review
- Review
- An overview of Charcot's neuroarthropathy.Journal of clinical & translational endocrinology · 2020Review
- How We Manage Bone Marrow Edema-An Interdisciplinary Approach.Journal of clinical medicine · 2020Article
- WNT Signaling in Disease.Cells · 2019Review
- Diabetic endothelial colony forming cells have the potential for restoration with glycomimetics.Scientific reports · 2019Article
- Corneal confocal microscopy detects severe small fiber neuropathy in diabetic patients with Charcot neuroarthropathy.Journal of diabetes investigation · 2018Article
- Role of bisphosphonates in the management of acute Charcot foot.World journal of diabetes · 2018Review
- Markers of Local Inflammation and Bone Resorption in the Acute Diabetic Charcot Foot.Journal of diabetes research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeCharcot neuropathy is characterized by bone destruction in a foot leading to deformity, instability, and risk of amputation. Little is known about the pathogenic mechanisms. We hypothesized that the bone-regulating Wnt/β-catenin and RANKL/OPG pathways have a role in Charcot arthropathy. PATIENTS AND
methods24 consecutive Charcot patients were treated by off-loading, and monitored for 2 years by repeated foot radiography, MRI, and circulating levels of sclerostin, dickkopf-1, Wnt inhibitory factor-1, Wnt ligand-1, OPG, and RANKL. 20 neuropathic diabetic controls and 20 healthy controls served as the reference.
resultsLevels of sclerostin, Dkk-1 and Wnt-1, but not of Wif-1, were significantly lower in Charcot patients than in the diabetic controls at inclusion. Dkk-1 and Wnt-1 levels responded to off-loading by increasing. Sclerostin levels were significantly higher in the diabetic controls than in the other groups whereas Wif-1 levels were significantly higher in the healthy controls than in the other groups. OPG and RANKL levels were significantly higher in the Charcot patients than in the other groups at inclusion, but decreased to the levels in healthy controls at 2 years. OPG/RANKL ratio was balanced in all groups at inclusion, and it remained balanced in Charcot patients on repeated measurement throughout the study.
interpretationHigh plasma RANKL and OPG levels at diagnosis of Charcot suggest that there is high bone remodeling activity before gradually normalizing after off-loading treatment. The consistently balanced OPG/RANKL ratio in Charcot patients suggests that there is low-key net bone building activity by this pathway following diagnosis and treatment. Inter-group differences at diagnosis and changes in Wnt signaling following off-loading treatment were sufficiently large to be reflected by systemic levels, indicating that this pathway has a role in bone remodeling and bone repair activity in Charcot patients. This is of particular clinical relevance considering the recent emergence of promising drugs that target this system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.